Kerry announced that it has made two significant biotechnology acquisitions that will expand its expertise, technology portfolio and manufacturing capabilities. The company reached agreement to acquire the leading biotechnology innovation company, c-LEcta while also confirming that it has acquired the Mexican based enzyme manufacture, Enmex.
c-LEcta is a leading biotechnology innovation company specializing in precision fermentation, optimized bio-processing and bio-transformation for the creation of high-value targeted enzymes and ingredients. Based in Leipzig, Germany and employing over 100 people, c-LEcta has established itself as a leading innovator in disruptive new sciences for the pharmaceutical market, with a strong pipeline of functional bioactives across food, beverage and other consumer markets.
Enmex is a well-established enzyme manufacturer based in Mexico, supplying multiple bio-process solutions for food, beverage and animal nutrition markets. With a long history of partnering with global customers, Enmex has a complementary enzyme portfolio and a strong manufacturing infrastructure, which will extend Kerry’s fermentation and enzyme manufacturing capabilities into Latin America.
